Cincinnati’s Healthcare Industry Gains Access to a Leader in Biotech Innovation
[pullquote]The Atlas partners are highly strategic and seasoned investors that have an exceptional ability to identify potentially revolutionary and profitable intellectual property. Tim Schigel, Cintrifuse Fund Manager[/pullquote]
The Cintrifuse Early Stage Capital Fund I, LLC announced its eighth major investment in $280 million Atlas Venture Fund X, L.P. Based in Cambridge, Massachusetts, Atlas Venture invests in early-stage biotechnology companies. With this investment, The Cintrifuse Fund brings a proven biotech innovator and company builder into Cincinnati’s startup ecosystem.
Atlas Venture is one of the nation’s leading biotechnology venture capital firms. Its unique investment strategy helps realize strong, consistent returns. Atlas’ recent success stories include CoStim, a startup focused on anti-cancer immune mechanisms, Stromedix, a drug company focusing on idiopathic pulmonary fibrosis, and Zafgen, which developed a revolutionary weight loss drug – Beloranib.
“The Atlas partners are highly strategic and seasoned investors with an exceptional ability to identify potentially revolutionary and profitable intellectual property within research universities and turn that into a robust business model,” said Cintrifuse Fund Manager Tim Schigel. “Our relationship with Atlas can assist the region’s top research institutions to foster cutting edge IP.”
[pullquote]We’re excited to be involved with the community and committed to working with Cincinnati Children’s Hospital and UC Health on research and investment opportunities. Bruce Booth, Partner at Atlas Ventures[/pullquote]
“Cincinnati has a robust and vibrant startup community and we’re looking forward to increasing our presence in the region,” said Bruce Booth, a partner at Atlas. “We’re excited to be involved with the community and committed to working with Cincinnati Children’s Hospital and UC Health on research and investment opportunities.”
The expertise of Atlas’ GPs (general partners) and the cutting edge nature of its portfolio companies will be a valuable source of knowledge and thought leadership for #StartupCincy. Their excellence in the biotech space adds a focused expertise that will benefit Cincinnati’s entire startup ecosystem.